Novagali Pharma Announces the Update of its "Document De Base" With the French Securities Market Authority ("Autorité des marchés financiers" - AMF)
Evry, France (ots/PRNewswire)
- Not for Distribution in the United States, Canada or Japan
Novagali Pharma, an emerging ophthalmic pharmaceutical company, announces that the update of its document de base was filed on September 12th , 2007 to the Autorité des marchés financiers (AMF).
This update concerns half-yearly IFRS accounts ended on June 30th,
2007. The document de base also announces that the product candidate
Vekacia(R) was filed on July 27, 2007 with the European Agency for
the Evaluation of Medicinal Product (EMEA), for marketing approval
for the treatment of Vernal Keratoconjunctivitis ("VKC").The document de base, registered on July 18, 2007 under number I.07-132 and its update are available free of charge from Novagali Pharma, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, 91000 Evry, France, on the AMF website (http://www.amf-france.org) and on the Novagali Pharma website (http://www.novagali.com).
The public attention is drawn to the chapter 4 of the document de base, entitled << Risk Factors >>.
This press release, the information contained herein, the registration document and the actualization of the registration document which is referred to, do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Novagali Pharma in any country. No offer to sell shares in Novagali Pharma has been made, nor will be made, prior to the official approval by the Autorité des marchés financiers (AMF) of a prospectus comprising the registration document, its actualization which is the subject of this press release, and an offering prospectus which will be submitted to the AMF at a future date.
Shares of Novagali Pharma may not be sold in the United States of America (as defined under Regulation S of the U.S. Securities Act of 1933, as amended) without registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. There will be no registration of all or part of the offering referred to in this press release in the United States nor any public offering of Novagali Pharma securities in the United States. This press release may not be distributed, either directly or indirectly, in the United States and does not constitute an offer to sell securities in the United States.
There is no offer in the United Kingdom. In the United Kingdom, this information is directed only at investment professionals within the meaning of Article 19(1) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 of the United Kingdom (the Order) or persons who fall within Article 49(1) of the Order, or any other person to whom Novagali Pharma may legally transmit an invitation or solicitation to invest under the Order.
About Novagali Pharma : http://www.novagali.com
Novagali Pharma is an emerging ophthalmic pharmaceutical company based in the Génopôle biocluster in Evry (France), that develops innovative products for all segments of the eye. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 8 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cationorm(R), a CE mark product for dry eye relief, and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome. Founded in 2000, Novagali Pharma has raised a total amount of Euro 44 million in 3 series of financing.
Contact:
Press contacts: Novagali Pharma, Geneviève Garrigos,
+33-1-69-87-40-20, +33-6-65-54-60-19,
genevieve.garrigos@novagali.com; Euro RSCG, Estelle Griffe,
+33-1-58-47-95-25, +33-6-23-75-09-23, estelle.griffe@eurorscg.fr